Title:The Emerging Roles of RASSF5 in Human Malignancy
VOLUME: 18 ISSUE: 3
Author(s):Shuofeng Li, Jingwei Teng, Haiqing Li, Feifei Chen* and Junnian Zheng*
Affiliation:Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu, Jiangsu Province Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, 84 West Huai-hai Road, Xuzhou 221002, Jiangsu
Keywords:RASSF5, tumor suppressor, promoter hypermethylation, therapeutic target, malignancy, apoptosis.
Abstract:Ras association domain family member 5 (RASSF5, also named NORE1) is an identified member of
the RASSF gene family which could bind selectively to activate Ras and function as an antineoplastic effector in
multiple cellular regulations. While highly expressed in majority of normal tissues, RASSF5 is epigenetically
inactivated by promoter hypermethylation in numerous cancer cell lines and primary cancers, suggesting it as a
potential tumor suppressor. Nevertheless, the physiologic significance of RASSF5 in tumorigenesis remains
unclear. We performed a systematic literature review and assessment from PUBMED and MEDLINE databases
in this article. RASSF5 is involved in a series of cellular responses including apoptosis, senescence, cell cycle
regulation, differentiation and cell proliferation and the inactivation of RASSF5 has been implicated to participate
in the oncogenesis, progression and poor prognosis of human cancers. In this review, we mainly elucidate
the acknowledged structure, progress in the verified functions and research advances of RASSF5 and the probably
relevant signaling pathways. Based on these evidences, potentiality of RASSF5 as a new therapeutic target
for human cancers may play a significant role in future oncotherapy.
